Skip to main content

Table 2 Treatment efficacy in patients (N = 17)

From: A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

Treatment efficacy No. of patients %
Response
 Overall response rate 13 76.4
 Disease control rate 15 88.2
 Complete response 1 5.9
 Partial response 12 70.6
 Stable disease 2 11.7
 Progressive disease 2 11.7
Survival
 Median PFS (months) 10.0 (95 % CI: 7.6–12.3 months)
 Median OS (months) 14.0 (95 % CI: 10.7–17.2 months)